Isotretinoin cumulative dose and acne relapse are linked, but the relationship isn’t a simple cutoff. The best evidence links low total exposure with more relapse. It doesn’t show that pushing every course above 120–150 mg/kg prevents relapse. A large cohort found the clearest association below 120 mg/kg. A 2026 trial detected no benefit from 150 versus 120 mg/kg. Let your prescriber balance clearance, tolerance and total exposure.
What cumulative dose actually means
Accutane is a familiar brand name for oral isotretinoin. It’s a prescription retinoid used mainly for severe acne, scarring risk or acne that hasn’t responded to standard treatment.
Daily dose is how much you take each day relative to body weight. Cumulative dose adds every dose across the course, then adjusts the total for body weight. A lower daily dose can reach the same cumulative total over a longer course. That may improve tolerability, but it doesn’t make monitoring optional.
NICE’s acne guideline uses 120–150 mg/kg as a course target. It also allows a clinician to finish earlier when skin has stayed clear for four to eight weeks. So the number is a treatment framework, not a pass-fail line. Our month-by-month isotretinoin guide explains how a course can unfold.
Isotretinoin cumulative dose and acne relapse: strongest evidence
The 2026 randomized trial by Cascio Ingurgio and colleagues gives the cleanest direct comparison. It assigned 91 patients with moderate-to-severe cystic acne to 120 or 150 mg/kg. Seventy-four completed treatment, and 64 had usable 12-month relapse data.
Relapse meant needing another topical or systemic treatment. It occurred in 8 of 30 patients at 120 mg/kg and 11 of 34 at 150 mg/kg. That was 26.7% versus 32.3%, with no statistically significant difference. The trial did not detect a benefit from 150 mg/kg. Its small sample and incomplete follow-up cannot prove the targets are equivalent.
Lai and Barbieri’s 2025 JAMA Dermatology cohort adds scale, not randomization. It followed 19,907 insured US patients for an average 24.9 months. Every included course lasted at least four months. Systemic-treatment relapse occurred in 22.5%, and 8.2% received another isotretinoin course.
Crude relapse rates were 26.1% below 120 mg/kg, 19.8% at 120–220 mg/kg and 22.2% above 220 mg/kg. After adjustment, higher cumulative exposure predicted less relapse only within the below-120 group. It did not predict less relapse inside either higher group.
Those numbers can’t establish a threshold. The database had no recorded body weights, so researchers estimated them from population averages matched by age and sex. It also lacked acne severity and end-of-course clearance. More persistent acne may receive longer treatment, creating confounding.
An older study helps explain the popular 220 mg/kg claim. Blasiak and colleagues enrolled 180 patients; 116 returned the 12-month survey. Crude relapse was 47.4% below 220 mg/kg and 26.9% at or above it.
That looks persuasive, but clinicians chose each dose. The higher-dose group was younger and stayed on treatment longer. After adjustment, the difference was not statistically significant. This observational result raises a hypothesis; it doesn’t justify a universal high target.
A 2023 systematic review by Daly and colleagues included 32 studies. Lower-dose courses tended to relapse more, while dryness and other mucocutaneous effects increased with dose. Yet relapse definitions, follow-up periods and regimens varied widely. The authors still called for an adequately powered randomized trial.
How to use the number in a real appointment
| Situation | What the evidence says | Useful question | Main limitation |
|---|---|---|---|
| Below 120 mg/kg with active acne | The large cohort found the clearest dose-relapse association within this range. | Are side effects, access or clinical response shaping the planned endpoint? | This was an observational association, not a personal cutoff. |
| Clear for four to eight weeks before 120 mg/kg | NICE allows earlier completion when a clinician judges clearance to be sustained. | Has clearance lasted, and what maintenance plan follows? | Early completion doesn’t guarantee permanent remission. |
| Near 120 mg/kg and considering 150 mg/kg | The randomized trial detected no lower 12-month relapse rate at 150 mg/kg. | Would an extension treat active acne or only pursue a number? | Only 64 patients contributed relapse data. |
| Above 220 mg/kg | The large cohort found no further adjusted relapse association. Older observational evidence suggested a benefit. | What specific expected benefit justifies more exposure? | High-dose evidence remains sparse and partly conflicting. |
Relapse figures don’t all mean the same thing
A new pimple, a topical prescription and a second isotretinoin course are different outcomes. Studies often group them differently. In Lai and Barbieri’s cohort, 22.5% received systemic treatment after the course. The figure rose to 35% when topical prescriptions were included, though topicals can serve as maintenance.
Among people counted as relapsing, the median time was 7.5 months. Nearly one-third relapsed after 12 months. A short flare does not by itself prove the course failed. Our guide to why acne returns after treatment explains other drivers and maintenance options.
Five questions matter more than chasing a target
- Am I clear yet? A dose total means less without the clinical response at the endpoint.
- How long has clearance lasted? NICE specifically allows sustained clearance to affect when a course ends.
- Why extend the course? Persistent lesions are a different reason from reaching a round number.
- What is limiting treatment? Dryness, laboratory changes, adherence and access may change the safest plan.
- What is the relapse plan? Ask what counts as recurrence, when to contact the clinic and whether maintenance is suitable.
These questions aren’t a basis for changing your own dose. Take them to the clinician who can see your acne, records and test results. New deep nodules or scarring deserve earlier review. This cystic acne guide explains when home care isn’t enough.
Keep the routine low-friction
Practical suggestion: use a gentle cleanser, plain moisturiser, lip balm and broad-spectrum sunscreen. Skip scrubs and new exfoliating acids while your skin is fragile. Ask before using topical retinoids or having waxing and other irritating procedures.
Dry lips and skin were common in both the 2013 cohort and 2026 trial. Report symptoms that interfere with eating, sleeping or daily function. Dose changes belong with your prescriber.
The safety rules do not shrink with the dose
Low daily or cumulative dosing still requires medical supervision. Isotretinoin can seriously harm an unborn baby and must not be used during pregnancy. Current UK MHRA rules retain the Pregnancy Prevention Programme. They also require follow-up monitoring for mental health and sexual-function effects.
US care uses iPLEDGE to manage embryo-fetal risk, while UK care follows MHRA and NICE rules. The requirements aren’t interchangeable. Follow the current plan from your local prescribing team.
Contact that team promptly about a pregnancy concern, new mood symptoms, thoughts of self-harm or sexual-function changes. Seek urgent help for thoughts of self-harm. No cumulative target guarantees permanent clearance. The useful endpoint is controlled acne with an acceptable safety burden, agreed with the prescriber monitoring you.
Oscar Nascimento
Editorial writer, GlowUp Face
Oscar writes about evidence-based skin care, healthcare, looksmaxxing, and the social and economic research surrounding appearance.
Full profile and all articles →
